NO20043859L - Pulversammensetning inneholdende zaleplon med definert partikkelstorrelsesfordeling og farmasoytiske produkter derav - Google Patents

Pulversammensetning inneholdende zaleplon med definert partikkelstorrelsesfordeling og farmasoytiske produkter derav

Info

Publication number
NO20043859L
NO20043859L NO20043859A NO20043859A NO20043859L NO 20043859 L NO20043859 L NO 20043859L NO 20043859 A NO20043859 A NO 20043859A NO 20043859 A NO20043859 A NO 20043859A NO 20043859 L NO20043859 L NO 20043859L
Authority
NO
Norway
Prior art keywords
particle size
composition containing
size distribution
powder composition
pharmaceutical products
Prior art date
Application number
NO20043859A
Other languages
English (en)
Inventor
Judith Aronhime
Erika Feher
Claude Singer
Ference Korodi
Csaba Szabo
Sheldon Deck
Original Assignee
Teva Gyogyszergyar Reszvenytar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Gyogyszergyar Reszvenytar filed Critical Teva Gyogyszergyar Reszvenytar
Publication of NO20043859L publication Critical patent/NO20043859L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20043859A 2002-02-15 2004-09-15 Pulversammensetning inneholdende zaleplon med definert partikkelstorrelsesfordeling og farmasoytiske produkter derav NO20043859L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35755202P 2002-02-15 2002-02-15
PCT/US2003/007267 WO2003068238A1 (en) 2002-02-15 2003-02-19 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom

Publications (1)

Publication Number Publication Date
NO20043859L true NO20043859L (no) 2004-09-15

Family

ID=27734754

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043859A NO20043859L (no) 2002-02-15 2004-09-15 Pulversammensetning inneholdende zaleplon med definert partikkelstorrelsesfordeling og farmasoytiske produkter derav

Country Status (14)

Country Link
US (1) US20050119281A1 (no)
EP (1) EP1490068A1 (no)
KR (1) KR20040086375A (no)
CN (1) CN101426504A (no)
AU (1) AU2003218058A1 (no)
CA (1) CA2475592A1 (no)
HR (1) HRP20040764A2 (no)
IL (1) IL163548A0 (no)
IS (1) IS7403A (no)
MX (1) MXPA04007937A (no)
NO (1) NO20043859L (no)
PL (1) PL373694A1 (no)
WO (1) WO2003068238A1 (no)
ZA (1) ZA200406577B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
CN101396364B (zh) * 2007-09-27 2011-10-26 北京天川军威医药技术开发有限公司 扎来普隆口腔给药系统或组合物及其制备方法
CN102670613A (zh) * 2011-03-16 2012-09-19 中国人民解放军军事医学科学院毒物药物研究所 用于改善茚地普隆溶出的药物组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
DE10004790B4 (de) * 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
WO2001078725A2 (en) * 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
PL365678A1 (en) * 2000-08-03 2005-01-10 Wyeth Polymorphs of zaleplon and methods for the preparation thereof
AR029780A1 (es) * 2000-12-13 2003-07-16 Gador Sa Procedimiento mejorado para la obtencion de n-[3(3-ciano-pirazolo[1,5-a]pirimidin-7-il)fenil]-n-etil-acetamida
HUP0402257A2 (hu) * 2001-06-12 2005-02-28 BIOGAL Gyógyszergyár Rt. Eljárás az N-[3-(3-cianopirazolo[1,5-a]pirimidin-7-il)-fenil]-N-etil-acetamid (zaleplon) előállítására
CA2453751A1 (en) * 2001-08-01 2003-02-13 Biogal Gyogyszergyar Rt. Purification and crystalline forms of zapelon
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders

Also Published As

Publication number Publication date
HRP20040764A2 (en) 2005-02-28
PL373694A1 (en) 2005-09-05
US20050119281A1 (en) 2005-06-02
AU2003218058A1 (en) 2003-09-04
KR20040086375A (ko) 2004-10-08
EP1490068A1 (en) 2004-12-29
IL163548A0 (en) 2005-12-18
WO2003068238A1 (en) 2003-08-21
MXPA04007937A (es) 2004-11-26
ZA200406577B (en) 2006-06-28
CA2475592A1 (en) 2003-08-21
IS7403A (is) 2004-08-13
CN101426504A (zh) 2009-05-06

Similar Documents

Publication Publication Date Title
HUP0302550A3 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines and pharmaceutical compositions containing them
IL213597A0 (en) Compounds, pharmaceutical compositions comprising them and their use in the manufacture of medicaments
IL162548A0 (en) 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
ZA200506240B (en) Coated particles and pharmaceutical dosage forms
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
HUP0400384A3 (en) Benzamidine derivative and pharmaceutical compositions containing them and their use
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
PL375860A1 (en) Benzodiazepine derivatives and pharmaceutical compositions containing them
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL166232A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
IL212477A0 (en) Biaryl heterocyclic compounds, methods of making the same, pharmaceutical compositions comprising them and their use in the preparation of medicaments
IL176384A (en) Pyrrolidinochlorinated basazole and pharmacy preparations containing them
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
IL164021A (en) Anti-αvβ6 antibodies and their pharmaceutical preparations
IL163894A (en) 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments
HUP0400052A3 (en) Carboxamide-substituted phenylurea derivatives and pharmaceutical compositions containing them and their use
HK1088543A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
HK1078086A1 (zh) 雜芳族五環化合物及其醫藥用途
IL168477A (en) Isoindoline derivatives and pharmaceutical compositions comprising them
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application